Contributions
Abstract: PB1635
Type: Publication Only
Session title: Myeloma and other monoclonal gammopathies - Biology & Translational Research
Background
Important role of certain cytokines in the regulation of hematopoiesis and immune response in multiple myeloma (MM) patients has been established. The lack of improvement in the quality of response after autologous hematopoietic stem cell transplantation (auto-HSCT), which is observed in some patients, may lead to decrease in the effectiveness of treatment. There is a little data on the significance of immune genes variations in predicting the effect of auto-HSCT in patients with MM.
Aims
To assess effect of several immune system genes (IL-6, TNF-A, IL-1B, IL-10) polymorphisms in patients with MM during auto-HSCT.
Methods
We included 28 MM patients (15 men and 13 women, mean age 53.7 ± 6.8 years) who underwent auto-HSCT in the study. Improvement in the quality of response after the first auto-HSCT was observed in 16 (57.1%) patients, whereas other 12 (42.9%) patients did not achieve such improvement. Genotyping for the IL-6 -174G/C, TNF-A -308G/A, IL-1B -31T/C, IL-10 -592C/A polymorphisms was performed by PCR-RFLP. Odds ratios (OR) and p-values were determined by Fisher’s exact test to characterize intergroup differences in distributions of genotypes and their combinations.
Results
Genotype frequencies for the TNF-A, IL-1B and IL-10 polymorphisms were not significantly different between the groups of patients with or without improvement in the quality of response after the first auto-HSCT. However, the frequency of homozygotes for the rare -592A allele of the IL-10 gene was almost 3 times higher in patients with improved quality of response than in those without improvement (20.0% vs 8.3%, respectively; p=0.12; OR=3.3). The frequency of the IL-1B -31TT genotype was also increased in patients with effective auto-HSCT when compared to “no improvement” group (37.5% vs 16.7%, respectively; p=0.4; OR=3.0). Finally, proportion of the IL-6 -174C allele carriers among patients with improved response was almost 2-fold higher (81.3% vs 41.6% in the group with no improvement in the quality of response; p=0.05; OR=6.1).
Conclusion
In this study, we observed possible association between the IL-6 -174G/C gene polymorphism and effectiveness of the first auto-HSCT in patients with MM. Further studies are needed to clarify the significance of immune genes variations in predicting the effect of auto-HSCT in patients with MM.
Keyword(s): Autologous hematopoietic stem cell transplantation, Cytokine, Gene polymorphism, Multiple myeloma
Abstract: PB1635
Type: Publication Only
Session title: Myeloma and other monoclonal gammopathies - Biology & Translational Research
Background
Important role of certain cytokines in the regulation of hematopoiesis and immune response in multiple myeloma (MM) patients has been established. The lack of improvement in the quality of response after autologous hematopoietic stem cell transplantation (auto-HSCT), which is observed in some patients, may lead to decrease in the effectiveness of treatment. There is a little data on the significance of immune genes variations in predicting the effect of auto-HSCT in patients with MM.
Aims
To assess effect of several immune system genes (IL-6, TNF-A, IL-1B, IL-10) polymorphisms in patients with MM during auto-HSCT.
Methods
We included 28 MM patients (15 men and 13 women, mean age 53.7 ± 6.8 years) who underwent auto-HSCT in the study. Improvement in the quality of response after the first auto-HSCT was observed in 16 (57.1%) patients, whereas other 12 (42.9%) patients did not achieve such improvement. Genotyping for the IL-6 -174G/C, TNF-A -308G/A, IL-1B -31T/C, IL-10 -592C/A polymorphisms was performed by PCR-RFLP. Odds ratios (OR) and p-values were determined by Fisher’s exact test to characterize intergroup differences in distributions of genotypes and their combinations.
Results
Genotype frequencies for the TNF-A, IL-1B and IL-10 polymorphisms were not significantly different between the groups of patients with or without improvement in the quality of response after the first auto-HSCT. However, the frequency of homozygotes for the rare -592A allele of the IL-10 gene was almost 3 times higher in patients with improved quality of response than in those without improvement (20.0% vs 8.3%, respectively; p=0.12; OR=3.3). The frequency of the IL-1B -31TT genotype was also increased in patients with effective auto-HSCT when compared to “no improvement” group (37.5% vs 16.7%, respectively; p=0.4; OR=3.0). Finally, proportion of the IL-6 -174C allele carriers among patients with improved response was almost 2-fold higher (81.3% vs 41.6% in the group with no improvement in the quality of response; p=0.05; OR=6.1).
Conclusion
In this study, we observed possible association between the IL-6 -174G/C gene polymorphism and effectiveness of the first auto-HSCT in patients with MM. Further studies are needed to clarify the significance of immune genes variations in predicting the effect of auto-HSCT in patients with MM.
Keyword(s): Autologous hematopoietic stem cell transplantation, Cytokine, Gene polymorphism, Multiple myeloma